Cresco Labs Inc (CRLBF) Fair Value & Analysis

Healthcare · US · Market cap $300M

Below-average quality, screening 200% undervalued on our models.

What matters now

• The large discount to fair value meets weak quality (34/100). That raises the risk this is a value trap rather than a bargain.
• The price is below even our cautious bear case ($1.53). The market is more pessimistic than our downside scenario.
• A fairly wide model range ($1.53 to $3.17) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range $0.4320 – $12.25 · fair‑value band $1.53 – $3.17 · the $0.7859 price screens below the $2.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Cresco Labs Inc (CRLBF) currently trades at $0.7859, while our model-based Fair Value estimate is $2.36, implying the stock looks roughly 200.0% undervalued today. The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Cresco Labs Inc generated revenue of $641M at a net margin of -20.9%. Revenue declined 8.7% year over year. It earns a return on equity of -45.8%. Net debt stands at $367M. Fundamentals as of Aug 13, 2026

Our scenario range runs from $1.53 (bear case) to $3.17 (bull case); at $0.7859, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 66% below its 52-week high and 84% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 200%, CRLBF screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples ($2.68) versus Dividend Discount ($0.0100). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States and Germany.

Full company description

Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States and Germany. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes, gummies, and pre-rolls under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company offers cannabis flowers under the FloraCal brand; and cannabis oils and variety of bites are available at multiple potency levels under the Mindy's brand, as well as Loud*r brand. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company is headquartered in Chicago, Illinois.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Cresco Labs Inc reported revenue of $656M in FY2025 versus $822M in FY2021, a compound −5.5%/yr. Reported net income was −$135M in FY2025.

Watch CRLBF: get an alert when its fair value changes →

Peer Group

Drug Manufacturers - Specialty & Generic · 634 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.